Published by Coherent Market Insights
Posted on September 30, 2021
Ulcerative Colitis Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Ulcerative Colitis Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/238
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Ulcerative colitis (UC), also known as colitis ulcerosa, is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is characterized by diarrhea, sudden and unexplained weight loss, loss of appetite, belly pain/cramps, bleeding from the rectum, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The inflammation results in development of tiny sores known as ulcers. Although the exact cause for UC is not known, probable factors include, genetic aspects, environmental changes, or weakened immune system. Healthy diet, proper hydration, skipping fatty foods, and limited consumption of high-fiber food can help to prevent UC. Although the incidence of the disease is high among people under 30 years of age, it may impact people of any age.
Colonoscopy, endoscopy, biopsy, CT scan, and blood test are some of the diagnostic methods of the disease. A patient may suffer from colon cancer if ulcerative colitis persists for over 8 years or longer. Over-the-counter drugs such as Imodium therapy, steroid medicines, and amino salicylates can be used for the treatment of cases with mild symptoms. Surgery is recommended in severe cases to remove the colon. Moreover, some genetically engineered drugs approved by the U.S. Food and Drugs Administration (FDA) such as Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade), and Vedolizumab (Entyvio) are used for the treatment of UC. These drugs made up of certain living organisms target the inflammatory proteins such as cytokines to suppress the inflammation. However, these drugs have some side effects such as low blood pressure, breathing difficulties, fever, headache, hives, back pain, stomach pain, and weakening of the immune system. Some of the major drugs used to reduce inflammation and swelling and for the treatment of UC include, Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), and Infliximab (Remicade).
Global Ulcerative Colitis Market Taxonomy:
Global Ulcerative Colitis Market by Drug Type
Infliximab
Golimumab
Adalimumab
Vedolizumab
Mesalamine
Budesonide
Balsazide
Global Ulcerative Colitis Market by Dosage Form
Parenteral
Oral
Global Ulcerative Colitis Market by Region
North America
Latin America
Asia Pacific
Middle East
Africa
Global Ulcerative Colitis Market: Drivers
Increasing incidence of UC is expected to boost growth of the global ulcerative colitis market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of UC is around 2.2 to 14.3 cases per 100,000 population per year. Moreover, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from UC in the U.S. (data based on the research conducted in between 2011-2014 by CCFA). According to the same source, the cases of UC are high in developed countries and the incidence of the disease is higher in urban areas compared to rural areas. Although, the disease can affect any age group, majority of the cases are between 15 to 35 years of age. According the stats of World Gastroenterology Organization (WGO), the prevalence of UC is increasing in emerging economies such as India, owing to changing diet and lifestyle.
Global Ulcerative Colitis Market: Regional Analysis
According to data collected from various sources and compiled by Coherent Market Insights, Europe has the highest annual rate of incidence of UC worldwide, followed by North America. The rate is the lowest in Asia Pacific and Middle East. North America is expected to hold dominant position in the global ulcerative colitis market over the forecast period. This is attributed to increasing R&D in drugs and awareness regarding the treatment of the disease.
Asia Pacific is expected to witness significant growth in the global ulcerative colitis market during the forecast period. This is attributed to increase prevalence of UC, R&D of new drugs, increasing awareness about the treatment of the disease, and loss of patent. For instance, Humira (adalimumab) lost its patent in 2016 and Remicade is expected to lose its patent in 2018. In 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.
Global Ulcerative Colitis Market: Competitive Landscape
Key players in the market are focused on R&D of novel drugs to expand their product portfolio. For instance, in October 2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness and safety in the treatment of ulcerative colitis in a 24-month open label extension study. In March 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Phase III data UNFI study data for Stelara, a subcutaneous maintenance therapy, which showed positive results as maintenance therapy in adults suffering from moderate to severe UC. In August 2019, Takeda Pharmaceutical Company Limited, submitted new drug application (NDA) to Ministry of Health, Labor and Welfare in Japan for subcutaneous formulation of vedolizumab, which will be used as maintenance therapy in adults with moderate to severe UC.
Major players operating in the global ulcerative colitis market include, Johnson and Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Hospira, Celltrion Healthcare, Warner Chilcott, Janssen Pharmaceuticals Inc., and Takeda Pharmaceuticals Company Ltd.
Buy This Premium Report Of Ulcerative Colitis Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/238
In this study, the years considered to estimate the market size of Ulcerative Colitis are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Ulcerative Colitis Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Ulcerative Colitis Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Ulcerative Colitis Market Size and Share | CAGR of 5.5% By 2027 appeared first on Gatorledger.
Ulcerative Colitis Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Ulcerative Colitis Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/238
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Ulcerative colitis (UC), also known as colitis ulcerosa, is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is characterized by diarrhea, sudden and unexplained weight loss, loss of appetite, belly pain/cramps, bleeding from the rectum, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The inflammation results in development of tiny sores known as ulcers. Although the exact cause for UC is not known, probable factors include, genetic aspects, environmental changes, or weakened immune system. Healthy diet, proper hydration, skipping fatty foods, and limited consumption of high-fiber food can help to prevent UC. Although the incidence of the disease is high among people under 30 years of age, it may impact people of any age.
Colonoscopy, endoscopy, biopsy, CT scan, and blood test are some of the diagnostic methods of the disease. A patient may suffer from colon cancer if ulcerative colitis persists for over 8 years or longer. Over-the-counter drugs such as Imodium therapy, steroid medicines, and amino salicylates can be used for the treatment of cases with mild symptoms. Surgery is recommended in severe cases to remove the colon. Moreover, some genetically engineered drugs approved by the U.S. Food and Drugs Administration (FDA) such as Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade), and Vedolizumab (Entyvio) are used for the treatment of UC. These drugs made up of certain living organisms target the inflammatory proteins such as cytokines to suppress the inflammation. However, these drugs have some side effects such as low blood pressure, breathing difficulties, fever, headache, hives, back pain, stomach pain, and weakening of the immune system. Some of the major drugs used to reduce inflammation and swelling and for the treatment of UC include, Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), and Infliximab (Remicade).
Global Ulcerative Colitis Market Taxonomy:
Global Ulcerative Colitis Market by Drug Type
Infliximab
Golimumab
Adalimumab
Vedolizumab
Mesalamine
Budesonide
Balsazide
Global Ulcerative Colitis Market by Dosage Form
Parenteral
Oral
Global Ulcerative Colitis Market by Region
North America
Latin America
Asia Pacific
Middle East
Africa
Global Ulcerative Colitis Market: Drivers
Increasing incidence of UC is expected to boost growth of the global ulcerative colitis market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of UC is around 2.2 to 14.3 cases per 100,000 population per year. Moreover, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from UC in the U.S. (data based on the research conducted in between 2011-2014 by CCFA). According to the same source, the cases of UC are high in developed countries and the incidence of the disease is higher in urban areas compared to rural areas. Although, the disease can affect any age group, majority of the cases are between 15 to 35 years of age. According the stats of World Gastroenterology Organization (WGO), the prevalence of UC is increasing in emerging economies such as India, owing to changing diet and lifestyle.
Global Ulcerative Colitis Market: Regional Analysis
According to data collected from various sources and compiled by Coherent Market Insights, Europe has the highest annual rate of incidence of UC worldwide, followed by North America. The rate is the lowest in Asia Pacific and Middle East. North America is expected to hold dominant position in the global ulcerative colitis market over the forecast period. This is attributed to increasing R&D in drugs and awareness regarding the treatment of the disease.
Asia Pacific is expected to witness significant growth in the global ulcerative colitis market during the forecast period. This is attributed to increase prevalence of UC, R&D of new drugs, increasing awareness about the treatment of the disease, and loss of patent. For instance, Humira (adalimumab) lost its patent in 2016 and Remicade is expected to lose its patent in 2018. In 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.
Global Ulcerative Colitis Market: Competitive Landscape
Key players in the market are focused on R&D of novel drugs to expand their product portfolio. For instance, in October 2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness and safety in the treatment of ulcerative colitis in a 24-month open label extension study. In March 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Phase III data UNFI study data for Stelara, a subcutaneous maintenance therapy, which showed positive results as maintenance therapy in adults suffering from moderate to severe UC. In August 2019, Takeda Pharmaceutical Company Limited, submitted new drug application (NDA) to Ministry of Health, Labor and Welfare in Japan for subcutaneous formulation of vedolizumab, which will be used as maintenance therapy in adults with moderate to severe UC.
Major players operating in the global ulcerative colitis market include, Johnson and Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Hospira, Celltrion Healthcare, Warner Chilcott, Janssen Pharmaceuticals Inc., and Takeda Pharmaceuticals Company Ltd.
Buy This Premium Report Of Ulcerative Colitis Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/238
In this study, the years considered to estimate the market size of Ulcerative Colitis are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Ulcerative Colitis Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Ulcerative Colitis Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Ulcerative Colitis Market Size and Share | CAGR of 5.5% By 2027 appeared first on Gatorledger.
Explore more articles in the Research Reports category
